US2004192606A1PendingUtilityA1

Method of promoting angiogenesis

55
Priority: Aug 15, 1995Filed: Apr 5, 2004Published: Sep 30, 2004
Est. expiryAug 15, 2015(expired)· nominal 20-yr term from priority
Inventors:Elaine Unemori
A61P 9/10A61P 9/00A61P 3/10A61P 41/00A61P 43/00A61P 3/00A61P 31/00A61P 17/02A61P 17/00A61K 38/2221
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Relaxin is useful for promoting angiogenesis and the treatment of infections or ischemic wounds where the injury results from lack of oxygen due to poor circulation.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for treating an infection or ischemic wound in a mammal in need thereof comprising administering a therapeutically effective amount of relaxin.  
     
     
         2 . The method of treatment of  claim 1  comprising the administration of relaxin in an amount sufficient to maintain a serum concentration of at least about 1 ng/ml.  
     
     
         3 . The method of treatment of  claim 1  comprising the administration of recombinant human relaxin (H2).  
     
     
         4 . The method of treatment of  claim 2  comprising the administration of recombinant human relaxin (H2).  
     
     
         5 . The method of treatment of  claim 3  wherein said relaxin is administered parenterally.  
     
     
         6 . The method of treatment of  claim 5  wherein said relaxin is administered by subcutaneous injection.  
     
     
         7 . The method of treatment of  claim 3  wherein said relaxin is administered by inhalation to the patient's respiratory tract.  
     
     
         8 . The method of treatment of  claim 3  wherein said infection or ischemic wound is one where the injury is the result from lack of oxygen due to poor circulation.  
     
     
         9 . The method of treatment of  claim 8  wherein said lack of oxygen due to poor circulation is the result of a disease.  
     
     
         10 . The method of treatment of  claim 9  wherein the disease is scleroderma or diabetes.  
     
     
         11 . The method of treatment of  claim 1  wherein the wound is an ischemic ulcer.  
     
     
         12 . A method for promoting angiogenesis in a mammal in need thereof comprising administering a therapeutically effective amount of relaxin.  
     
     
         13 . The method of  claim 12  comprising the administration of relaxin in an amount sufficient to maintain a serum concentration of at least about 1 ng/ml.  
     
     
         14 . The method of  claim 12  comprising the administration of recombinant human relaxin (H2).  
     
     
         15 . The method of  claim 13  comprising the administration of recombinant human relaxin (H2).  
     
     
         16 . The method of  claim 14  wherein said relaxin is administered parenterally.  
     
     
         17 . The method of  claim 16  wherein said relaxin is administered by subcutaneous injection.  
     
     
         18 . The method of  claim 14  wherein said relaxin is administered by inhalation to the patient's respiratory tract.  
     
     
         19 . A method of using relaxin for the manufacture of a medicant for the treatment of an infection or ischemic wound.  
     
     
         20 . The method of  claim 19  wherein the relaxin is recombinant human relaxin (H2).  
     
     
         21 . A method of using relaxin for the manufacture of a medicant for the promotion of angiogenesis.  
     
     
         22 . The method of  claim 21  wherein the relaxin is recombinant human relaxin (H2).

Join the waitlist — get patent alerts

Track US2004192606A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.